Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Pemetrexed + Cisplatin + Radiotherapy vs Etoposide + Cisplatin + Radiotherapy in Unresectable Stage III NSCLC (Non-squamous)
KCT0001060Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Eli Lilly and Company. Started Oct 2011; status: terminated.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0001060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001060.